ZYKADIA (ceritinib), tyrosine kinase inhibitor

High clinical benefit and minor clinical added value compared to chemotherapy combining a platinum salt and pemetrexed, followed by maintenance treatment with pemetrexed, as first line treatment of metastatic non-small cell lung cancer with ALK gene rearrangement

• ZYKADIA has been granted marketing authorisation for the first-line treatment of adults in monotherapy for advanced metastatic non-small cell lung cancer (NSCLC) with ALKgene rearrangement.

• Its superiority has been demonstrated over platinum salt-based chemotherapy in terms of progression-free survival, though without demonstrated impact on overall survival. This chemotherapy, however, is no longer the current treatment standard.

• Its safety profile is superior to that of chemotherapy.

• It is a first-line treatment for this population.